HF
MGX icon

HRT Financial’s Metagenomi Therapeutics MGX Stock Holding History

HRT Financial’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,674
Closed -$14K – 5535
2026
Q1 		$14K Sell
10,674
-417
-4% -$648 ﹤0.01% 3609
2025
Q4 		$17K Sell
11,091
-3,006
-21% -$6.51K ﹤0.01% 3003
2025
Q3 		$33K Sell
14,097
-44,946
-76% -$91.2K ﹤0.01% 2649
2025
Q2 		$87K Buy
+59,043
New +$92.5K ﹤0.01% 2227
2024
Q2 		– Sell
-31,477
Closed -$332K – 3258
2024
Q1 		$332K Buy
+31,477
New +$362K ﹤0.01% 1497

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HRT Financial's MGX Position: Q2 2026 in Review

HRT Financial sold out of Metagenomi Therapeutics (MGX) in Q2 2026, closing a stake of 10,674 shares — an estimated $14K sold.

HRT Financial first reported a position in MGX in Q1 2024 and held it in 5 quarters. The position peaked at $332K in Q1 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • HRT Financial reported no remaining Metagenomi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 10,674 Metagenomi Therapeutics shares in Q2 2026, an estimated $14K.
  • HRT Financial first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 5 quarters.
  • HRT Financial's Metagenomi Therapeutics position peaked at $332K in Q1 2024.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.